1. MAPK/ERK Pathway
  2. JNK
  3. JAK3-IN-13

JAK3-IN-13 (compound 12n) is a potent, selective and orally active JAK3 inhibitor with IC50 values of 4728, 2039, 8, 365 nM for NK1, JNK2, JNK3, Tyk2, respectively. JAK3-IN-13 shows antiproliferative activity. JAK3-IN-13 induces cell cycle arrest at G0/G1 phase. JAK3-IN-13 shows antitumor activity.

For research use only. We do not sell to patients.

JAK3-IN-13 Chemical Structure

JAK3-IN-13 Chemical Structure

CAS No. : 2803329-86-2

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  
Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Top Publications Citing Use of Products

View All JNK Isoform Specific Products:

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

JAK3-IN-13 (compound 12n) is a potent, selective and orally active JAK3 inhibitor with IC50 values of 4728, 2039, 8, 365 nM for NK1, JNK2, JNK3, Tyk2, respectively. JAK3-IN-13 shows antiproliferative activity. JAK3-IN-13 induces cell cycle arrest at G0/G1 phase. JAK3-IN-13 shows antitumor activity[1].

IC50 & Target[1]

JNK1

4728 nM (IC50)

JNK2

2039 nM (IC50)

JNK3

8 nM (IC50)

Tyk2

365 nM (IC50)

In Vitro

JAK3-IN-13 (compound 12n) (10 μM; 72 h) shows antiproliferative activity in BaF3-JAK3M511I, U937, parental cells[1].
JAK3-IN-13 inhibits the activity of TEL-JNK1, TEL-JNK2, JNK3M511I, JNK3 with IC50 values of 177.7, 134.2, 22.9, 1.2 nM, respectively[1].
JAK3-IN-13 inhibits (0-800 nM; 0-24 h) decreases the expression of phosphorylation JAK3, STAT3, and STAT5 in a dose-dependent manner[1].
JAK3-IN-13 inhibits (0-330 nM; 24 h) induces cell cycle arrest at G0/G1 phase and down-regulates the expression of cyclin-dependent kinase 2 (CDK2), CDK4, CDK6, cyclin B1, cyclin D3, and cyclin E1 in a concentration-dependent manner[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay[1]

Cell Line: BaF3-JAK3M511I, U937, parental, COLO-205, H1299, HCT-116, MDA-MB-231, AGS, HL 7702 cells
Concentration: 10 μM
Incubation Time: 72 h
Result: Showed antiproliferative activity with IC50s of 22.9, 20.2, 165.1 nM for BaF3-JAK3M511I, U937, parental cells, and >10, >10, >10, >10, >10, 3.27 μM for COLO-205, H1299, HCT-116, MDA-MB-231, AGS, HL 7702 cells, respectively.

Western Blot Analysis[1]

Cell Line: U937 cells
Concentration: 0-800 nM
Incubation Time: 0-24 h
Result: Dose-dependently suppressed the phosphorylation of JAK3, STAT3, and STAT5 and achieved near-complete inhibition at 200 nM.

Cell Cycle Analysis[1]

Cell Line: U937 cells
Concentration: 0-330 nM
Incubation Time: 24 h
Result: Induced cell cycle arrest at G0/G1 phase and down-regulated the expression of cyclin-dependent kinase 2 (CDK2), CDK4, CDK6, cyclin B1, cyclin D3, and cyclin E1 in a concentration-dependent manner.
In Vivo

JAK3-IN-13 (5 mg/kg for i.v.; 15 mg/kg for p.o.) shows good PK properties and oral bioavailability of 20.66%[1].
JAK3-IN-13 (12.5, 25, 50 mg/kg; p.o.; twice daily for 10 days) shows antitumor activity and inhibits the expression of phosphorylation JAK3, STAT3, STAT5, CDK2, CDK4, CDK6, cyclin B1, cyclin D3, and cyclin E1[1]. Pharmacokinetic Parameters of JAK3-IN-13 in Male Sprague-Dawley rats[1].

12n i.v.(5 mg/kg) p.o.(15 mg/kg)
anminal no. 3 3
T1/2 (h) 0.91 0.98
Cmax (ng/mL) 911.33 238.28
AUC(0-∞) (h·ng/mL) 536.99 333.50
CL (mL/min/kg) 155.22
F % 20.66
Male Sprague-Dawley rats, 5 mg/kg iv (5% DMSO + 10% solutol + 85% saline); 15 mg/kg po (0.5% HPMC in water)[1]

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male Sprague-Dawley rats[1]
Dosage: 5 mg/kg for i.v.; 15 mg/kg for p.o.
Administration: I.v. or p.o.
Result: Showed good PK properties and oral bioavailability of 20.66%.
Animal Model: Male CB17-SCID mice (U937 mouse xenograft model)[1]
Dosage: 12.5, 25, 50 mg/kg
Administration: P.o.; twice daily for 10 days (10 mg/kg; i.p.; once daily)
Result: Dose-dependently inhibited the growth of the U937 tumor and significantly inhibited the expression of phosphorylation JAK3, STAT3, and STAT5 as well as the cell cycle-related proteins.
Molecular Weight

533.02

Formula

C25H33ClN6O5

CAS No.
SMILES

C=CC(NC1=CC(NC2=NC=C(Cl)C(O[C@H]3[C@](OC[C@H]4OC)([H])[C@]4([H])OC3)=N2)=CC=C1N(CCN(C)C)C)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
JAK3-IN-13
Cat. No.:
HY-150688
Quantity:
MCE Japan Authorized Agent: